| protein
| Philadelphia chromosome breakpoint, BCR ( |
|
cyclic AMP response element (CRE)-binding protein, CREB |
|
abl-interactor 2, ABI2 ( |
|
Grb2 and mSos1 ( |
|
SHPTP1 ( |
|
ABL-associated protein 1, AAP1 ( |
|
v-crk sarcoma virus CT10 oncogene homolog (avian)-like, CRKL ( |
|
ataxia telangiectasia mutated, ATM ( |
|
phosphoprotein associated with glycosphingolipid, PAG ( |
|
Src family kinase Hck ( |
|
paxillin, PXN ( |
|
amphiphysin-like protein 1, ALP1 ( |
|
growth factor receptor-bound protein 10, GRB10 ( |
|
Janus kinase 1, Jak1 ( |
|
70 kDa subunit of Ku antigen, Ku70 ( |
|
glucokinase (hexokinase 4) regulator, GCKR ( |
|
p73alpha ( |
|
Dok-like protein, DOKL ( |
|
P53 ( |
|
Trk nerve growth factor receptor ( |
|
TrkA ( |
|
rapamycin and FKBP-target 1, RAFT1 ( |
|
N-methyl-D-aspartic acid receptor NR2D subunit ( |
|
telomerase reverse transcriptase, TERT ( |
|
roundabout, axon guidance receptor, homolog 1, ROBO1 ( |
|
Cdk5 and Abl enzyme substrate, Cables ( |
|
WAVE-1 ( |
|
CD19 ( |
|
p21-activated protein kinase gamma-PAK ( |
|
hematopoietic progenitor kinase 1, HPK1 ( |
|
Fe65, X11, and mDab1 ( |
|
phospholipid scramblase 1, PLSCR1 ( |
|
proto-oncogene Vav ( |
|
RAN, member RAS oncogene family, RAN ( |
|
EPH receptor B2, EPHB2 ( |
|
Brain armadillo protein delta-catenin ( |
|
RAD9 homolog A (S. pombe), RAD9 ( |
|
anterior pharynx-defective 2, Aph2 ( |
|
BRCA1 ( |
|
damage-specific DNA binding protein 1, DDB1 ( |
|
IkappaBalpha ( |
|
Crk SH2 domain ( |
|
Arg/Abl-interacting protein ArgBP2 ( |
|
Arg protein-tyrosine kinases ( |
|
catalase ( |
|
glutathione peroxidase 1, GPx1 ( |
|
Ras and Rab interactor 1, RIN1 ( |
|
topoisomerase (DNA) II binding protein 1, TOPBP1 ( |
|
vinexin ( |
|
mucin 1, cell surface associated, MUC1 ( |
|
FGFR1OP and WRNIP1 (FGFR1OP significantly reduced ABL1-dependent phosphorylation of WRNIP1 and resulted in the promotion of cell cycle progression) |
|
amplified in breast cancer 1 protein, AIB1 ( |
|
role for MSH5 in DNA damage response involving ABL1 and TP73, suggesting that mutations impairing this process could significantly affect normal cellular responses to anti-cancer treatments |
|
CDON is important for full ABL1 kinase activity, and ABL1 is necessary for full activation of MAPK14, during myogenic differentiation |
|
PARK2 (ABL1 SH3 domain is required for the interaction with parkin) |
|
Atm and Atr in response to DNA damage ( |
|
EWSR1 depletion results in alternative splicing changes of genes involved in DNA repair and genotoxic stress signaling, including ABL1, CHEK2, and MAP4K2 |
|
H2O2-NOX5 regulation in human spermatozoa is mediated through a ABL1-dependent signaling pathway |
|
mediates oxidative stress-induced neuronal cell death through phosphorylating STK4 at Y433 |
|
is a novel upstream activator of STK3 suggesting that the conserved ABL1-MST signaling cascade plays an important role in oxidative stress-induced neuronal cell death |
|
KAT5 tyrosine phosphorylation is a key event in the sensing of genomic and chromatin perturbations, with a key role for ABL1 in such processes |
|
functional relationship between ABL1 and CLASP2 is conserved and provides a means to control the CLASP2 association with the cytoskeleton |
|
ABL1 protected HIPK2 from degradation mediated by the ubiquitin E3 ligase SIAH1 |
|
ABL1 phosphorylates SKI-interacting protein (SNW1), a nuclear cofactor of the transcription factor SMAD3 |
|
ERRFI1 may regulate the targeting of ABL1 to chromatin |
